Abbreviations used in this paper: CHX, cycloheximide; DISC, death-inducing signaling complex; IAP, inhibitor of apoptosis; RPA, RNase protection assay; siRNA, small interfering RNA.

Introduction
============

In susceptible cells, membrane FasL, agonistic Fas-specific antibodies, and secondarily aggregated soluble FasL induce reorganization of inactive, preassembled Fas complexes to supramolecular Fas clusters having the capacity to signal apoptosis. Upon formation of apoptosis-competent signaling clusters, Fas is able to recruit the cytoplasmic death domain--containing adaptor protein FADD (Fas-associated death domain protein), which in turn recruits procaspase-8. In context of this death-inducing signaling complex (DISC), procaspase-8 is activated by dimerization ([@bib2]; [@bib6]), resulting in autoproteolytic processing and release of the mature and active heterotetrameric form of the enzyme. In so called type I cells, Fas-activated caspase-8 is sufficient to trigger efficient activation of effector caspases, especially caspase-3, resulting in execution of the final steps of apoptosis ([@bib1]). In contrast, in type II cells, caspase-8 activation is less prominent and/or caspase-3 activation is counteracted by members of the inhibitor of apoptosis (IAP) protein family ([@bib1]). In these cells, robust induction of apoptosis is therefore dependent on mitochondrial amplification mechanisms that can be triggered by caspase-8--mediated cleavage of Bid, a BH3-only protein. The resulting truncated Bid fragment induces Bax/Bak-dependent release of apoptogenic proteins from mitochondria including Smac/Diablo (the second mitochondria-derived activator of caspase/direct IAP binding protein with low PI), HtrA2/Omi, and cytochrome *c* ([@bib1]). Although cytosolic cytochrome *c* assembles with ATP and the scaffold protein Apaf-1 (apoptosis promoting factor-1) to the apoptosome ([@bib41]), which activates caspase-9, Smac/Diablo and HtrA2/Omi block caspase inhibition by members of the IAP protein family ([@bib49]). Both mechanisms enhance the effect of initially DISC-activated caspase-8. Due to cell type--specific relative contributions of these proapoptotic mitochondrial events to Fas-induced apoptosis, type I and type II cells have been experimentally defined in vitro by overexpression of Bcl2 or other proteins interfering with the Bax/Bak-mediated release of apoptogenic factors. In type I cells, death receptor--induced apoptosis was not affected by Bcl2 expression, whereas in type II cells Bcl2 expression inhibited or attenuated Fas-induced apoptosis. If and to which extent the release of mitochondrial proteins can contribute to the apoptotic effects of Fas in vivo is a matter of debate. Although some reports found a protective effect in hepatocytes of Bcl2 transgenic mice against Fas-mediated apoptosis induced by agonistic antibodies ([@bib27]; [@bib40]), others found no protective effect by Bcl2 when Fas was challenged with aggregated soluble FasL ([@bib18]). The latter study has shown in vitro that agonistic Fas-specific antibodies, but not cross-linked FasL, are much more active on type I cells than on type II cells. Therefore, these apparent discrepancies in various studies might be caused by analyzing Fas signals of different strengths. Embryonal fibroblasts of Apaf1-deficient mice ([@bib3]) displayed somewhat lower Fas sensitivity, and Fas-mediated liver toxicity is also reduced in mice deficient for Bid ([@bib55]) or Bak and Bax ([@bib53]). In contrast, thymocytes of Bcl2 transgenic mice ([@bib45]; [@bib18]), of caspase-9--deficient mice ([@bib12]), and of Bak/Bax double-deficient mice ([@bib35]) as well as Bcl2-expressing granulocytes ([@bib50]) showed no significant decrease in Fas sensitivity, suggesting a cell type--specific nonessential contribution of the intrinsic mitochondrial apoptotic pathway to Fas-induced apoptosis.

Fas-induced apoptosis is inhibited by the long and short isoform of the cellular FLICE-inhibitory protein cFLIP. Similar to caspase-8, FLIP~L~ (FLIP-long) consists of two amino-terminal death effector domains followed by an unfunctional caspase homology domain ([@bib26]; [@bib47]). FLIP~S~ (FLIP-short) has no caspase homology domain and mainly consists of the two death effector domains of the long isoform. Although FLIP~S~ blocks autoproteolytical maturation of Fas-FADD--bound caspase-8 completely, FLIP~L~ arrests this process at an intermediate state ([@bib26]; [@bib47]).

Although Fas has been predominantly recognized as an apoptosis inducer, there is increasing evidence for additional apoptosis-independent functions of Fas, including induction of proliferation in T cells and fibroblasts, hepatocyte regeneration, chemokine production, DC regulation, and neurite outgrowth (for review see [@bib5]; [@bib52]). However, the molecular mechanisms of Fas signaling in most of these processes are poorly understood. In this study, we identified FADD, caspase-8, and RIP as essential components of Fas-induced NFκB signaling. Moreover, we showed that FLIP~S~ and especially FLIP~L~ have an inhibitory role in Fas-induced NFκB activation.

Results
=======

Bcl2 expression in HT1080 and KB cells confers resistance against Fas-induced apoptosis
---------------------------------------------------------------------------------------

Active caspases cleave components of the NFκB signaling cascade and efficiently inhibit activation of this pathway during apoptosis (for review see [@bib52]). Therefore, we decided to analyze FasL-induced NFκB signaling and gene induction in cells protected from the apoptotic action of FasL. This can be achieved in type I and type II cells by inhibition of caspases; e.g., by pharmacological inhibitors or by expression of FLIP and in vitro in type II cells, which show a strong contribution of the intrinsic apoptotic pathway to Fas-induced apoptosis, in addition by Bcl2 overexpression. We choose the latter possibility, in contrast to pharmacological caspase-8 inhibitors and FLIP, as Bcl2 does not target the Fas signaling complex and should therefore have no influence on receptor proximal events in Fas signaling. We used KB and HT1080 cells as well as transfectants derived thereof that have been stably transfected with a GFP fusion protein of Bcl2 ([Fig. 1](#fig1){ref-type="fig"} A). FasL-induced apoptosis in parental KB cells required sensitization by cycloheximide (CHX), an inhibitor of protein synthesis. Parental HT1080 cells already underwent significant Fas-induced apoptosis in the absence of CHX, but nevertheless responded more strongly in the presence of CHX (unpublished data). Noteworthily, the CHX concentrations used (2.5 μg/ml or less) only reduced overall protein synthesis for 10 to 30% and resulted only in marginal cell death even after extended incubation times (unpublished data). Thus, in the time scale of our analysis, CHX treatment predominantly affected expression levels of short-lived proteins including antiapoptotic factors (e.g., FLIP). Parental KB and HT1080 cells both have an ED50 value for FasL-induced apoptosis of around 0.3--2 ng/ml. The KB-GFP-Bcl2 transfectants have an ED50 value of \>1 μg/ml and HT1080-GFP-Bcl2 cells showed only marginal apoptosis (\<10%) at FasL concentrations \>1,000-fold higher than those necessary to kill the parental cells ([Fig. 1](#fig1){ref-type="fig"} B). Next, we checked if KB and HT1080-GFP-Bcl2 cells are protected against apoptosis induction by cells expressing membrane FasL. For this purpose, we assayed cocultures of the various cells with Rapo cells and Rapo transfectants expressing membrane FasL ([Fig. 1](#fig1){ref-type="fig"} C). Rapo cells are a Jurkat clone devoid of Fas expression, and these cells are therefore resistant against Fas-induced apoptosis. Rapo-FasL cells induced complete killing of KB and HT1080 cells in coculture assays, whereas the parental Rapo clone showed no effect. In contrast, KB-GFP-Bcl2 and HT1080-GFP-Bcl2 cells were completely (KB) or largely (HT1080) protected against the membrane FasL-expressing Rapo cells. Apoptosis induction by Rapo-FasL was blocked by the caspase inhibitor z-IETD-fmk and Fas-Comp, a pentameric fusion protein containing the extracellular domain of Fas ([Fig. 1, D and E](#fig1){ref-type="fig"}). Thus, in KB and HT1080 cells the intrinsic apoptotic pathway makes a significant contribution to Fas-induced apoptosis, even when Fas is stimulated with membrane FasL and allows analysis of nonapoptotic Fas signaling.

![**Bcl2 expression protects HT1080 and KB cells from Fas-mediated apoptosis.** (A) FACS^®^ analysis of pools of HT1080 and KB cells stably transfected with GFP-Bcl2. (B) Indicated cells were seeded in 96-well plates (20 × 10^3^ per well) and challenged the next day with the indicated concentrations of soluble Flag-tagged FasL complexed with 0.5 μg/ml of the Flag-specific mAb M2 in the presence of 2.5 μg/ml CHX. After an additional 18 h, cell viability was determined by crystal violet staining. (C) Cells were seeded in 96-well plates overnight, and the next day the indicated number of membrane FasL-expressing Rapo cells or parental Rapo cells were added to each well in the presence of 2.5 μg/ml CHX. After 18 h, Rapo, Rapo-FasL, and dead cells were removed by two washes with PBS, and finally, the remaining viable cells were quantified by crystal violet staining. HT1080 (D) and KB (E) cells were challenged with Rapo-FasL cells as described in C. However, this time either the HT1080 and KB cells were pretreated with 50 μM of the caspase-8 inhibitor z-IETD-fmk or the Rapo-FasL cells with 4 μg/ml of Fas-Comp. Viability data shown are averages and SDs of triplicates.](200401036f1){#fig1}

Fas-mediated NFκB activation and gene induction in Bcl2-protected cells
-----------------------------------------------------------------------

Next, we analyzed FasL-induced IL8 production, as this chemokine is a well established target gene of nonapoptotic Fas signaling and of pivotal importance for FasL-induced tumor cell rejection (for review see [@bib52]). Although in KB cells there was only a minor increase in IL8 production upon Fas stimulation, significant amounts of IL8 were induced in HT1080 cells ([Fig. 2](#fig2){ref-type="fig"} A). Remarkably, in the presence of the caspase inhibitor z-VAD-fmk, which blocks apoptosis and the NFκB inhibitory effects of caspases, FasL-induced IL8 production in HT1080 cells was three to five times higher. Similarly, the low induction of IL8 in KB cells was also enhanced in the presence of z-VAD-fmk. In the presence of low doses of CHX (2.5 μg/ml), thus under circumstances where Fas induces activation of caspases and apoptosis, FasL-induced IL8 production was almost completely blocked in both cell lines. In the case of KB cells, there was a higher basal IL8 production in the presence of CHX ([Fig. 2](#fig2){ref-type="fig"} A). However, when apoptosis induction was blocked by z-VAD-fmk, FasL-induced IL8 production was restored and even significantly higher than in the absence of CHX. These data not only illustrate that the low concentrations of CHX used had indeed no major effect on overall protein synthesis but also suggest that CHX facilitates Fas-induced IL8 production by bringing a short-lived inhibitory protein under a critical threshold. Bcl2 expression was sufficient to substitute z-VAD-fmk to allow enhanced FasL-mediated induction of IL8. Thus, in HT1080-GFP-Bcl2 cells, FasL-induced IL8 production reached comparable levels as in z-VAD-fmk--protected parental HT1080 cells ([Fig. 2](#fig2){ref-type="fig"} A). Treatment of HT1080-GFP-Bcl2 cells with z-VAD-fmk did not lead to a further enhancement of IL8 production. In contrast to the parental cell lines, CHX treatment did not interfere or even sensitize the GFP-Bcl2 transfectants for FasL-induced IL8 production. In the presence of CHX and the absence of apoptosis (z-VAD-fmk and GFP-Bcl2 expression), FasL-induced IL8 levels almost reached values induced by TNF, which is a very potent inducer of IL8 production (unpublished data). IL8 production was similarly induced when membrane FasL-expressing cells were used instead of cross-linked soluble FasL ([Fig. 2](#fig2){ref-type="fig"} B). Together, these data suggest that a CHX-sensitive, and therefore short-lived, protein exists that blocks both apoptosis and gene induction by FasL upstream of Bcl2. In accordance with the central role of NFκB in regulation of the IL8 gene ([@bib14]), FasL activated the NFκB pathway in z-VAD-fmk-- and Bcl2-protected cells ([Fig. 3, A and B](#fig3){ref-type="fig"}). IκBα degradation was transient and rapid upon TNF stimulation ([Fig. 3](#fig3){ref-type="fig"} B). In contrast, a delayed and sustained loss of IκBα protein was observed after FasL treatment in KB and HT1080 cells and in the corresponding Bcl2-transfectants in the presence of 2.5 μg/ml CHX ([Fig. 3](#fig3){ref-type="fig"} B). To analyze the genes induced by FasL more comprehensively and, at the same time, compare them to TNF, we determined the expression of 110 genes relevant to inflammation using a customized DNA oligonucleotide microarray developed in our laboratory ([@bib16]). In HT1080-GFP-Bcl2 cells, 40 genes were significantly expressed, 16 of which were induced by FasL by at least 1.5-fold on average and 27 by TNF ([Table I](#tbl1){ref-type="table"}). Inspection of the more strongly regulated genes revealed that FasL and TNF, despite their different kinetics of NFκB activation, induced an almost identical pattern of genes. Moreover, many of the induced genes are established targets of the NFκB pathway; e.g., such as ICAM-1, CCL2, IL8, JunB, or IκBα. Together, these studies demonstrated that at least in vitro Bcl2 expression can convert a proapoptotic Fas signal into an inflammatory NFκB-related response.

![**FasL induces IL8 in Bcl2-protected HT1080 and KB cells.** (A) Indicated cells were seeded in 96-well plates (20 × 10^3^ per well). The next day, the medium was changed and cells were stimulated with 200 ng/ml of soluble Flag-tagged FasL complexed with 0.5 μg/ml of the Flag-specific mAb M2 or 20 ng/ml TNF in the presence of the indicated reagents (20 μM z-VAD-fmk; 2.5 μg/ml CHX). After 6 h, supernatants were removed, cleared, and analyzed for their IL8 content using an IL8-specific ELISA. (B) Cells were seeded in 96-well plates (20 × 10^3^ per well). The next day, the medium was changed and Rapo or Rapo-FasL cells (40 × 10^3^ per well) were added for 6 h in the presence or absence of 20 μM z-VAD-fmk and finally IL8 production was determined as in A. Data shown are averages and SDs of triplicates.](200401036f2){#fig2}

![**FasL induces NFκB activation in Bcl2-protected HT1080 and KB cells.** (A) HT1080 and HT1080-GFP-Bcl2 cells were stimulated with M2--cross-linked Flag-FasL (200 ng/ml) or TNF (20 ng/ml), and in the case of the parental cells, the presence of 20 μM z-VAD-fmk. After 3 h, cells were analyzed for NFκB activation by electrophoretic mobility shift assay. (B) Indicated cells were stimulated for varying times with cross-linked Flag-FasL or TNF, and IκBα degradation was determined by Western blot analysis of cytosolic extracts with an IκBα-specific antibody. To control protein loads, filters were reprobed with antitubulin antibodies. Where indicated, 20 μM z-VAD-fmk and 2.5 μg/ml CHX were added 1 h before stimulation.](200401036f3){#fig3}

###### Comparison of the effects of FasL and TNF on inducible inflammatory gene expression of HT1080-Bcl2 cells

                                                            Relative induction                        
  ---------------------------------- ---------------------- -------------------- --------- ---------- ----------
  Signalling molecules                                                                                
  NM_001165                          hlAP-1                 **11.0**             **4.0**   **28.1**   **5.1**
  NM_020529                          IκB-α                  **7.5**              **7.4**   **9.3**    **9.1**
  NM_001561                          ILA                    **2.7**              **0.9**   **7.4**    **1.9**
  NM_002229                          JunB                   **4.1**              **2.0**   **3.0**    **2.7**
  NM_001166                          hlAP-2                 0.9                  1.6       1.8        1.6
  NM_031419                          MAIL                   1.8                  1.2       1.6        1.8
  NM_002228                          c-Jun                  1.3                  1.4       0.9        0.8
  Metabolic enzymes, miscellaneous                                                                    
  NM_002852                          PTX3                   **6.0**              **5.1**   **15.3**   **9.8**
  NM_000636                          MnSOD                  **2.8**              **1.5**   **6.5**    **5.1**
  NM_002575                          PAI-2                  **3.2**              **1.4**   **5.0**    **3.2**
  NM_000161                          GTP cyclohydrolase I   1.4                  0.8       1.8        1.8
  NM_001993                          Tissue factor          1.5                  1.0       1.1        0.9
  NM_004385                          Versican               1.3                  0.5       1.0        1.1
  NM_002032                          Ferritin heavy chain   1.2                  0.8       1.0        1.0
  NM_000602                          PAI-1                  0.9                  1.2       0.9        0.9
  Proteases                                                                                           
  NM_002428                          MMP15                  **5.1**              **2.0**   **8.8**    **4.1**
  NM_004994                          MMP9                   **2.1**              **1.4**   **5.9**    **5.4**
  NM_002427                          MMP13                  1.3                  0.9       1.3        3.2
  NM_002422                          MMP3                   1.0                  0.8       1.4        1.2
  Cytokines--cytokine receptors                                                                       
  NM_000575                          IL-1 α                 **4.9**              **2.3**   **9.1**    **3.9**
  NM_000758                          GM-CSF                 **4.0**              **1.4**   **8.1**    **3.5**
  NM_000576                          IL-1 β                 **3.1**              **2.2**   **7.6**    **6.2**
  NM_001066                          TNFR II                1.7                  0.6       3.0        1.4
  NM_000882                          IL-12A (p35)           1.4                  1.1       1.7        1.9
  NM_002341                          Lymphotoxin β          1.3                  0.9       1.6        1.5
  NM_002006                          bFGF                   1.1                  0.7       1.4        1.1
  NM_005228                          EGFR                   0.9                  0.9       1.1        0.9
  NM_003266                          TLR 4                  1.1                  0.8       1.0        1.3
  NM_000594                          TNF α                  1.4                  1.9       0.9        1.6
  NM_004513                          IL-16                  0.9                  0.5       0.8        1.1
  NM_001901                          CTGF                   1.7                  0.9       0.7        0.5
  Chemokines--chemokine receptors                                                                     
  NM_002982                          CCL2                   **6.6**              **2.5**   **40.7**   **14.6**
  NM_000584                          CXCL8                  **14.8**             **8.1**   **38.4**   **13.5**
  NM_002985                          CCL5                   **1.2**              **0.9**   **2.3**    **1.5**
  NM_002986                          CCL11                  **1.2**              **0.7**   **1.8**    **1.6**
  NM_001295                          CCR1                   **1.6**              **0.8**   **1.5**    **2.1**
  NM_000648                          CCR2b                  1.1                  0.8       0.9        1.1
  Adhesion molecules                                                                                  
  NM_000201                          ICAM1                  **2.2**              **1.8**   **4.1**    **4.3**
  Acute phase genes                                                                                   
  NM_000331                          SAA 1                  **2.2**              **1.4**   **3.4**    **3.5**
  NM_001639                          SAP                    0.8                  0.8       1.7        1.9

HT1080-Bcl2 cells were treated with 200 ng/ml FasL for 6 h or left untreated. Parallel cells were treated with 20 ng/ml TNF for 6 h. Thereafter, total RNA was isolated from all samples and used to prepare double-stranded cDNA followed by cRNA synthesis. cRNA was labeled with Cy3 and hybridized independently to DNA microarrays containing amino-modified oligonucleotide probes, representing 110 genes relevant to inflammation as well as several housekeeping genes. Fluorescence intensities of bound cRNAs were recorded, normalized, and used to identify 40 inflammatory genes that were significantly expressed. Alterations imposed by the FasL or TNF on the inducible or basal expression of these genes were determined as a ratio of relative gene expression compared with unstimulated cells. The results from two independent experiments are shown (Exp. 1 and 2). Genes are arranged into functional groups and are ordered according to their relative induction by TNF in Exp. 1. GenBank accession numbers and gene names, respectively, are provided for identification. Genes induced for more than twofold by TNF or FasL are in bold.

Fas-induced up-regulation of IκBα occurs via FADD, caspase-8, and RIP
---------------------------------------------------------------------

Next, we investigated Jurkat cells because for this cell type a variety of clones are available with defects in the expression of proteins related to NFκB and/or Fas signaling. In Jurkat cells, FasL did not induce IL8. We analyzed instead IκBα, which is a bona fide NFκB target gene ([@bib23]). Jurkat cells are highly sensitive toward FasL-induced apoptosis in the absence of CHX. To ensure analysis of nonapoptotic Fas signaling, we blocked caspase activity and apoptosis by adding z-VAD-fmk. Under these conditions, all parental Jurkat strains responded to FasL treatment with IκBα induction ([Fig. 4, A and B](#fig4){ref-type="fig"}, left). First, we analyzed a Jurkat clone deficient in expression of NEMO/IKKγ, a crucial component of the IKK complex ([@bib23]), which therefore fails to activate the NFκB signaling pathway in response to a variety of inducers ([@bib13]). In agreement with the idea that FasL-induced up-regulation of IκBα is due to the activation of NFκB, this effect was completely abolished in the NEMO/IKKγ-deficient Jurkat clone ([Fig. 4](#fig4){ref-type="fig"} A, middle). FasL-induced up-regulation of IκBα also occurred in the presence of high concentrations of CHX (25--50 μg/ml), which fully block protein synthesis, indicating that IκBα induction is a direct consequence of Fas signaling (unpublished data). We also analyzed Jurkat cells deficient in the expression of the serine/threonine kinase RIP, which was originally identified as a death domain--containing Fas-interacting protein ([@bib44]) and which plays an essential role in NFκB activation by the death receptors TNF-R1 and TRAIL-R1 ([@bib48]; [@bib24]; [@bib34]). FasL-induced up-regulation of IκBα was completely blocked in RIP-deficient Jurkat cells ([Fig. 4](#fig4){ref-type="fig"} A, right), indicating that this kinase is also critically involved in Fas-induced NFκB activation. Remarkably, induction of cJun, which is regulated by AP1 and the JNK pathway, was only marginally affected ([Fig. 4](#fig4){ref-type="fig"} A).

![**FasL-induced IκBα up-regulation occurs via a FADD, caspase-8, RIP-dependent pathway in Jurkat cells.** (A and B) RIP- (A), NEMO/IKKγ- (A), FADD- (B), and caspase-8 (B)--deficient Jurkat clones and the corresponding parental cell lines were treated for 6 h with the indicated combinations of M2--cross-linked Flag-FasL (200 ng/ml), TNF (20 ng/ml), and z-VAD-fmk (20 μM). Total RNAs were isolated for RPA analyses and 10 μg of each RNA sample were analyzed with a Multi-Probe template set containing probes for the indicated mRNAs. Parental Jurkat cells were challenged with cross-linked FasL alone, but a reliable RPA analysis was not possible due to the massive induction of apoptosis leading to a strong reduction of the mRNA fraction in total RNA isolated.](200401036f4){#fig4}

FADD and caspase-8 are essential components of the DISC of Fas ([@bib1]) and are also indispensable for FasL-induced up-regulation of cFos, which occurs in Jurkat cells under nonapoptotic circumstances ([@bib42]). Analysis of FADD and caspase-8--deficient Jurkat clones ([@bib21], [@bib22]) revealed that both proteins are also necessary for FasL-induced up-regulation of IκBα ([Fig. 4](#fig4){ref-type="fig"} B). Fas signaling occurred in the presence of z-VAD-fmk, when caspase-8 activity was completely blocked. Thus, caspase-8 acts in FasL-induced NFκB signaling independent from its enzymatic activity. Moreover, FasL-induced cJun up-regulation was also completely blocked in FADD and caspase-8--deficient clones ([Fig. 4](#fig4){ref-type="fig"} B). Together these data suggest that FADD and caspase-8 form a core signaling complex with Fas, whose structural integrity is necessary to allow activation of a diverse set of otherwise independent signaling pathways.

FLIP inhibits Fas-mediated up-regulation of NFκB target genes
-------------------------------------------------------------

Apoptosis induction and NFκB activation by Fas bifurcate at the level of FADD and caspase-8. Therefore, the potential short-lived inhibitor, which concomitantly blocks apoptotic and nonapoptotic Fas signaling, should target the Fas signaling complex. As discussed in an earlier work ([@bib51]), good candidates for such short-lived protein(s) are the FLIP isoforms as they (a) act on the Fas DISC and (b) exert the required high turnover ([Fig. 5](#fig5){ref-type="fig"} A; [@bib9]; [@bib29]; [@bib51]; [@bib25]). In further agreement with a negative-regulatory role of FLIP proteins in FasL-induced NFκB signaling, we found that FasL-induced up-regulation of IκBα is completely absent in a Jurkat clone stably transfected with FLIP~L~ ([Fig. 5](#fig5){ref-type="fig"} B). Notably, the expression level of FLIP~L~ in this clone does not exceed endogenous FLIP~L~ expression levels observed in other cell lines or mature dendritic cells ([Fig. 5, A and C](#fig5){ref-type="fig"}; [@bib25]). A Jurkat clone transfected with FLIP~S~ showed normal FasL-induced up-regulation of IκBα (unpublished data), but it cannot be ruled out that this was due to limited expression of FLIP~S~. Further, we observed that the FasL-induced response pattern in primary cells also supports an NFκB inhibitory role of FLIP. In mature dendritic cells having high endogenous levels of FLIP ([Fig. 5](#fig5){ref-type="fig"} C; [@bib30]; [@bib39]; [@bib54]), FasL showed no effect on IκBα expression ([Fig. 5](#fig5){ref-type="fig"} D, middle), whereas in primary T cells having barely detectable FLIP expression ([Fig. 5](#fig5){ref-type="fig"} C; [@bib19]), IκBα mRNA was readily induced ([Fig. 5](#fig5){ref-type="fig"} D, left and right). In the latter case, addition of z-VAD-fmk was required, as otherwise apoptosis interferes with the NFκB response. To analyze the role of FLIP~L~ and FLIP~S~ in Fas-mediated gene induction in KB and HT1080 cells, we produced pools of transfectants stably expressing GFP fusion proteins of FLIP~L~ and FLIP~S~, respectively. All FLIP~L/S~ expressing KB and HT1080 populations (KB-FLIP~L/S~-GFP and HT1080-FLIP~L/S~-GFP) showed unchanged Fas expression (not depicted) and were highly resistant against FasL-induced apoptosis also in the presence of CHX ([Fig. 6, A and B](#fig6){ref-type="fig"}). Although in z-VAD-fmk-- and Bcl2-protected KB and HT1080 cells FasL strongly induced IL8 production, in FLIP~L~- and FLIP~S~-protected cells Fas-mediated IL8 up-regulation was blocked ([Fig. 6, C and D](#fig6){ref-type="fig"}). The inhibitory effect of FLIP~L~ and FLIP~S~ on IL8 production was specific for Fas, as TNF-induced IL8 up-regulation, which occurs via the Fas-related death receptor TNF-R1, only insignificantly varied for maximally 33% between the parental cells and the corresponding transfectants. Changes in basal IL8 production were negligible in the FLIP~L/S~-transfected KB populations ([Fig. 6, C and D](#fig6){ref-type="fig"}). However, the FLIP~L~ and especially the FLIP~S~-expressing HT1080 cells showed significantly increased levels of constitutive IL8 production ([Fig. 6, C and D](#fig6){ref-type="fig"}). Similar effects were also found in respect to NFκB activation (unpublished data). Thus, dependent on the cell type, FLIP~S~ and to a lesser extend FLIP~L~ can have opposing effects, namely inhibition of Fas-inducible NFκB activation and up-regulation of NFκB by another yet unknown mechanism. FACS^®^ analysis of the FLIP-GFP--expressing cells and EGFP FACS^®^ calibration beads showed that 60--80% of the KB transfectants expressed \<116,000 molecules of the GFP fusion proteins per cell, whereas the rest of the cells expressed \>116,000 molecules per cell ([Fig. 6](#fig6){ref-type="fig"} A). In TNF-stimulated KB cells ([Fig. 7](#fig7){ref-type="fig"} B), mature DCs, and, as a positive control in the Hodgkin cell line L591 ([Fig. 5](#fig5){ref-type="fig"}), endogenous expression of FLIP~L~ reached 0.25, 4, and 3 fg per cell; and FLIP~S~ reached 0.5 and 6 fg per cell in KB and L591 cells. This corresponds to ∼3,000 to 50,000 FLIP~L~ molecules and 15,000 to 180,000 FLIP~S~ molecules per cell. As the inhibitory effects on FLIP~L~-GFP and FLIP~S~-GFP expression in KB cells were around 90% ([Fig. 6](#fig6){ref-type="fig"} D), these data indicate that "physiological" levels of FLIP~L~ and FLIP~S~ are sufficient to block FasL-induced IL8 production. Next, we down-regulated expression of endogenous FLIP proteins by RNA interference--mediated gene silencing using the synthetic small interfering RNA (siRNA) F1, recognizing both FLIP isoforms ([Fig. 7](#fig7){ref-type="fig"} A; [@bib43]), and a new siRNA, F1490, which down-regulate FLIP~L~ but not FLIP~S~ ([Fig. 7, A and B](#fig7){ref-type="fig"}). In KB cells electroporated with the FLIP-specific siRNAs, FasL-induced IL8 production was substantially enhanced, as compared with cells mock electroporated or electroporated with control siRNA ([Fig. 7](#fig7){ref-type="fig"} C). The increase of FasL-induced IL8 production reached by siRNA treatment was comparable, although FLIP~S~ expression significantly exceeded FLIP~L~ expression in KB cells ([Fig. 5](#fig5){ref-type="fig"} A and 7 B). This finding suggests that FLIP~L~ is more efficient than FLIP~S~ in inhibition of Fas-induced NFκB activation. Basal IL8 production was also specifically increased in F1490- and F1-siRNA electroporated cells ([Fig. 7](#fig7){ref-type="fig"} C). Thus, although in HT1080 cells that ectopically expressed FLIP~S~ or FLIP~L~ basal IL8 production was increased, endogenously expressed FLIP had an inhibitory role in KB cells. These opposing effects on Fas-independent basal IL8 production might reflect cell type--specific and/or FLIP isoform--specific functions of FLIP not related to Fas signaling (see Discussion).

###### 

**FLIP~L~ inhibits FasL-induced IκBα up-regulation.** (A) 10^6^ L591 Hodgkin, KB, or Jurkat FLIP~L~ cells were treated for the indicated times with 50 μg/ml CHX and were analyzed with respect to expression of FLIP~L~ and FLIP~S~ by Western blotting with a FLIP-specific antibody. To control protein loads, filters with L951 and KB cells were reprobed with an antitubulin antibody, and a FLIP~L~-GFP mass standard, which was normalized via its GFP part, was processed on the same filter to allow a quantitative estimation of FLIP expression. Based on this standard, FLIP~L~ expression corresponds to 3,000 (KB) and 36,000 (L591) molecules per cell and FLIP~S~ expression to 15,000 (KB) and 180,000 (L591) molecules per cell. (B) Parental Jurkat cells and a clone derived thereof, which stably overexpresses FLIP~L~, were challenged with the indicated combinations of soluble Flag-tagged FasL (200 ng/ml) cross-linked with the Flag-specific mAb M2 (0.5 μg/ml), TNF (20 ng/ml), and z-VAD-fmk (20 μM) for 6 h; and 10 μg of total RNA were used for RPA analyses with respect to the expression of the indicated target genes. (C) Cell lysates corresponding to 10^6^ primary T cells, immature and mature DCs, and Jurkat-FLIP~L~ transfectants were analyzed with respect to expression of FLIP~L~ and FLIP~S~ by Western blotting with a FLIP-specific antibody. Based on the FLIP~L~-GFP mass standard, FLIP~L~ expression corresponds to 50,000 molecules per cell in mature DCs and Jurkat-FLIP~L~ cells. (D) Human (left) and murine T cell blasts (right) as well as fully mature human dendritic cells (DCs; middle) were challenged for 6 h with M2--cross-linked Flag-FasL (200 ng/ml) in the presence of z-VAD-fmk. Total RNAs were finally analyzed with respect to expression of the indicated genes by RPA analysis.
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###### 

**FLIP~L~ and FLIP~S~ protect HT1080 and KB cells from Fas-mediated apoptosis and block FasL-induced IL8 production.** (A) FACS^®^ analysis of GFP FACS^®^ calibration beads with 0 (labeled "A"), 4,500 (labeled "B"), 15,000 (labeled "C"), 44,000 (labeled "D"), and 116,000 (labeled "E") molecules of equivalent soluble fluorochrome as well as HT1080 and KB cell stably transfected with FLIP~L~-GFP or FLIP~S~-GFP. In the case of the KB cells, the localization of the calibration beads was corrected according to a minor difference in the autofluorescence of the parental cells and the nonfluorescent beads. (B) Indicated cells were seeded in 96-well plates (20 × 10^3^ per well) and challenged with the indicated concentrations of soluble Flag-tagged FasL complexed with 0.5 μg/ml of the Flag-specific mAb M2 in the presence of 2.5 μg/ml CHX the next day. After an additional 18 h, cell viability was determined by crystal violet staining. (C) The indicated transfectants and cell lines were seeded in 96-well plates (20 × 10^3^ per well). The next day, the medium was changed and cells were stimulated in triplicates with the indicated combinations of 200 ng/ml of cross-linked Flag-FasL, 20 ng/ml TNF, 20 μM z-VAD-fmk, and 2.5 μg/ml CHX. After 6 h, supernatants were removed and cleared, and IL8 concentrations were determined by ELISA analysis. (D) HT1080 and KB cells and FLIP~L~-GFP and FLIP~S~-GFP transfectants derived thereof were challenged for 6 h with 200 ng/ml of M2--cross-linked Flag-FasL or 20 ng/ml TNF in the presence of 20 μM z-VAD-fmk (HT1080) or a mixture of 2.5 μg/ml CHX and 20 μM Z-VAD-FMK (KB). Total RNAs were isolated and the expression of the indicated genes was determined by RPA analysis.
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![**Down-regulation of endogenous FLIP~L~ is sufficient to enhance Fas-mediated IL8 production.** (A) Expression plasmids for FLIP~L~-GFP, FLIP~S~-GFP, and DsRED were transiently transfected in triplicate with siRNAs (150 nM) specific for GFP (S15), FLIP~L~ (F1490), or for both FLIP isoforms (F1). As a control, the various plasmids were cotransfected with a Bcl2-specific siRNA. After 48 h, cells were analyzed by FACS^®^, and relative expression levels were calculated from the product of the percentage of positive cells and the mean fluorescence intensity of positive cells. (B) The indicated siRNAs (150 nM) were introduced into KB cells by electroporation. The next day, expression of FLIP~L~ and FLIP~S~ was up-regulated by TNF stimulation (20 ng/ml) and determined by Western blot analysis of cell extracts with a FLIP-specific antibody. To control protein loads, filters were reprobed with antitubulin antibodies. (C) KB cells were seeded in 96-well plates (20 × 10^3^ per well). 1 d later, cells were mock transfected (open bars) or transfected with control siRNA (hatched bars), a FLIP~L/S~-specific siRNA (F1; black bars), or a FLIP~L~-specific siRNA (F1490; gray bars). After an additional day, medium was changed and cells were stimulated for 6 h with 200 ng/ml of M2--cross-linked Flag-FasL or 20 ng/ml TNF. Finally, IL8 production was measured by ELISA analysis.](200401036f7){#fig7}

Discussion
==========

The Fas-induced signaling pathways leading to up-regulation of IκBα and cJun were completely blocked in FADD- and caspase-8--deficient Jurkat cells in our study ([Fig. 4](#fig4){ref-type="fig"} B). Moreover, induction of apoptosis and necrosis as well as up-regulation of cFos, which most likely occurs via the ERK pathway, have also been reported to be blocked in the FADD-deficient Jurkat clone used in our study ([@bib22]; [@bib15]; [@bib42]). Further, with the exception of necrosis induction, all these Fas-induced processes are also abrogated in caspase-8--deficient Jurkat cells ([@bib21]; [@bib15]; [@bib42]). Together this suggests that upon stimulation Fas forms a core signaling complex with FADD, which is essentially involved in all Fas-mediated signaling pathways ([Fig. 8](#fig8){ref-type="fig"}). With the exception of necrosis induction, caspase-8 is necessary for all other Fas signaling events. Noteworthily, only apoptosis induction appears to be dependent on the proteolytic activity of caspase-8 arguing for an additional scaffolding-related function of caspase-8 in context of the Fas signaling complex. Although RIP is necessary for Fas-induced NFκB activation ([Fig. 4](#fig4){ref-type="fig"} A) and necrosis induction ([@bib15]), this kinase seems dispensable for the pathway(s) leading to up-regulation of cJun and cFos ([Fig. 4](#fig4){ref-type="fig"}; [@bib42]). For the reasons outlined in the next paragraph in detail, FLIP~L/S~ appear to have an inhibitory role for all of these Fas-dependent signaling events by targeting the Fas/FADD--caspase-8 core complex. However, there is also evidence in the literature for Fas-independent signaling properties of FADD, caspase-8, and FLIP.

![**Model of Fas signaling pathways.** Relations 1--3, 7--9, and 10 are based on literature data (see Discussion for details). Relations 3--6 are evident from data shown in [Fig. 5](#fig5){ref-type="fig"}. Relations 11--13 are based on experiments shown in [Figs. 1](#fig1){ref-type="fig"}--[4](#fig4){ref-type="fig"} and [7](#fig7){ref-type="fig"}.](200401036f8){#fig8}

Transient overexpression experiments have revealed NFκB-inducing capacities of FADD, caspase-8, FLIP~L~, and FLIP~S~ ([@bib4]; [@bib17]; [@bib51]). Moreover, several studies have shown that stimulation of Fas can also result in NFκB activation, suggesting at first glance that a FADD/caspase-8/FLIP~L~ (or FLIP~S~)--containing complex mediates this response (for review see [@bib31]; [@bib52]). However, there are several concerns arguing against this simple concept. NFκB activation by overexpression of FADD, FLIP~L~, or FLIP~S~ is blocked by proteins (CrmA and p35) and reagents (BD-fmk and z-VAD-fmk) that prevent caspase-8 activation ([@bib4]; [@bib17]). In contrast, NFκB activation induced by overexpressed caspase-8 or stimulated Fas are rather enhanced by inhibition of caspase-8 activity ([@bib4]; [@bib17]; [@bib51]). Nevertheless, as shown in [Fig. 4](#fig4){ref-type="fig"} B, FasL-induced up-regulation of IκBα was completely absent in FADD and caspase-8--deficient cells. Thus, it seems possible that FADD and caspase-8 are not only necessary for caspase activity--independent Fas-induced NFκB activation but may also act in a Fas-independent but caspase activity--dependent NFκB-inducing pathway. We have further identified in this study RIP as an essential component of Fas-induced NFκB signaling. In accordance with this finding, it has been reported that a dominant-negative deletion mutant of RIP blocks NFκB activation induced by transiently overexpressed FADD and Fas ([@bib17]). Notably, in this study, dominant-negative RIP failed to inhibit NFκB activation by overexpressed FLIP ([@bib17]), arguing again for the existence of a Fas-independent role of FLIP in a yet unknown pathway leading to NFκB activation. Further, RIP is cleaved by caspase-8, resulting in an NFκB-inhibitory fragment ([@bib33]). Recent studies suggest that enzymatically active heteromers of caspase-8 and FLIP~L~ can be formed within the Fas signaling complex. Thus, the FLIP~L~-arrested DISC may also lead to the cleavage of RIP arguing against an NFκB-activating role of FLIP~L~ in Fas signaling. It should be briefly mentioned here that Fas also induces necrosis in Jurkat cells under crucial involvement of RIP, but independent from NEMO/IKKγ ([@bib15]; unpublished data). Thus, Fas-induced NFκB and necrosis signaling bifurcate at the level or downstream of RIP ([Fig. 8](#fig8){ref-type="fig"}). The Fas-independent NFκB-inducing capabilities of FLIP~L/S~ might be related to the NFκB-activating properties of the viral FLIP homologue HHV8 vFLIP that interacts with the IKK complex ([@bib36]; [@bib8]). Indeed, similarly to overexpressed FLIP~L/S~, HHV8 vFLIP activates NFκB independent of RIP ([@bib38]). Moreover, HT1080 cells stably transfected with FLIP~S~, which is more closely related in its domain architecture to HHV8 vFLIP than FLIP~L~, showed a significantly higher basal NFκB activity than FLIP~L~-expressing HT1080 cells ([Fig. 6](#fig6){ref-type="fig"}). FLIP effects not related to Fas signaling might also be based on the recently described interaction of FLIP~L~ with NFκB1/p105 ([@bib32]) and p38MAPK ([@bib11]).

Opposing effects of FLIP have also been reported with respect to T cell activation. Although overexpressed FLIP~L~ enhances TCR-induced ERK activation and IL2 production in Jurkat cells, it reduces these responses in DO11.10 T cells ([@bib7]). Moreover, in one study, increased proliferation in FLIP-transgenic T cells upon stimulation with suboptimal concentrations of anti-CD3 has been observed ([@bib28]), whereas in another study several transgenic lines with T cell--restricted FLIP expression exerted suppression of T cell activation over a wide range of anti-CD3 concentrations ([@bib46]). However, the precise effects of FLIP on Fas signaling had not been addressed in these studies as no experiments with Fas stimulation have been performed. In KB and HT1080 cells, Bcl2 overexpression increased the ED50 value for FasL-induced apoptosis more than 500-fold ([Fig. 1](#fig1){ref-type="fig"} B), suggesting an almost essential contribution of the intrinsic apoptotic pathway to Fas-induced apoptosis. However, in vivo, a significant contribution of the intrinsic pathway has so far only been observed in some studies when Fas was challenged with Fas-specific agonistic antibodies, making the physiological relevance of the intrinsic pathway for the in vivo effects of Fas a matter of debate. However, it should be taken into consideration that not only the specific cell type is of relevance for the question of whether a contribution of the intrinsic pathway to Fas-induced apoptosis gets apparent but also the strength of Fas activation and the time point after Fas triggering. Indeed, it has been shown in vitro that agonistic Fas antibodies alone are significantly less efficient than cross-linked soluble FasL or secondary aggregated Fas antibodies to kill type II cells ([@bib18]). Noteworthily, in the studies showing protection against Fas-induced liver failure in Apaf1- ([@bib3]), Bid- ([@bib55]), or Bax- and Bak ([@bib53])-deficient mice, a suboptimal amount of agonistic antibodies was used to activate Fas. In contrast, in a study that fails to observe Bcl2-mediated protection against the hepatotoxic effects of Fas activation, cross-linked FasL was used ([@bib18]). This suggests that there is no essential role of the intrinsic pathway in Fas-induced apoptosis in vivo but rather an accelerative and/or enhancing contribution, especially after a limited activation of Fas. Delayed apoptosis induction via Fas should already be sufficient to allow transient activation of the NFκB pathway by the mechanisms described in our study and might be of special relevance for the proinflammatory effects of FasL observed in various models of FasL-mediated tumor rejection. Although Fas-induced NFκB activation depends on caspase-8, the enzymatic activity of the latter appeared to be dispensable ([Figs. 2](#fig2){ref-type="fig"}--[5](#fig5){ref-type="fig"}). Thus, Fas-induced NFκB activation may attain importance under pathophysiological conditions where caspase-8 activity is blocked, e.g., by viral inhibitors such as CrmA or where caspase-8 is mutated.

Materials and methods
=====================

Reagents
--------

Human recombinant Flag-tagged soluble FasL was purified from supernatants of Hek293 cells stably transfected with a corresponding expression plasmid by affinity chromatography with anti-FLAG M2 agarose beads (Sigma-Aldrich). Human recombinant TNF was obtained from Knoll AG. z-VAD-fmk was purchased from Bachem and z-IETD-fmk was obtained from Calbiochem. CHX, the anti-Flag mouse mAb M2, and alkaline phosphatase--conjugated goat anti--mouse IgG were purchased from Sigma-Aldrich. The anti-FLIP mouse mAb NF-6 was purchased from Qbiogene. The human epidermal cell line KB and the human fibrosarcoma cell line HT1080 were both obtained from the American Type Culture Collection. The Jurkat T cell lines deficient for FADD, caspase-8, NEMO/IKKγ, and RIP were supplied by J. Blenis (Harvard Medical School, Boston, MA), B. Seed (Massachusetts General Hospital, Boston, MA), and S.-C. Sun (Pennsylvania State University College of Medicine, Hershey, PA) and are described elsewhere ([@bib48]; [@bib21], [@bib22]; [@bib13]). The Jurkat clones overexpressing FLIP~L~ and FLIP~S~, respectively, were supplied by P. Schneider and J. Tschopp (University of Lausanne, Epalinges, Switzerland) and are described by [@bib19]. The F1 siRNA corresponds to positions 472--494 of U97074 (sense: 5′-atgtggttccacctaatgtca-3′; antisense: 5′-tgacattaggtggaaccacatct-3′) and F1490 to positions 1785 to 1805 whereby A1788 was substituted to G to match the mouse sequence (sense: 5′-agcacacucugaggaagaaac-3′; antisense: 5′-guuucuuccucagagugugcugc-3′).

Cell culture
------------

KB, HT1080, and Jurkat cells were maintained in RPMI 1640 medium containing 10% heat-inactivated FCS in a humified 5.0% CO~2~ environment. For generation of polyclonal cell populations stably overexpressing GFP-fusion proteins, 10 × 10^6^ cells were electroporated (4 mm cuvette; 250 V, 1800 μF, maximal resistance) with 10 μg of plasmid DNA in medium with 5% FCS. After 14 d of selection with 400--800 μg/ml G418 (GIBCO BRL), primary clones (*n* \> 100) were pooled, expanded, and enriched for cells expressing the GFP-fusion proteins by two to three rounds of cell sorting using a FACStar^Plus^ (Becton Dickinson). A Fas-negative, CD3-responsive Jurkat subclone ([@bib20]) was electroporated with a pEFBos-derived vector encoding full-length FasL and a hygromycin resistance vector (provided by B. Schraven, Otto-von-Guericke-University, Magdeburg, Germany). Resistant clones (Rapo-FasL) obtained were selected for high FasL membrane expression and subcloned under limiting dilution conditions. Human monocyte-derived dendritic cells were prepared and characterized as recently described ([@bib31]). Human and murine T cells were prepared as described by [@bib10] and [@bib37], respectively.

Cell death assays, Western blotting, and electrophoretic mobility shift assay analysis
--------------------------------------------------------------------------------------

These techniques were performed as described previously ([@bib51]; [@bib25]).

IL8-ELISA
---------

Cells were seeded in 96-well cell culture plates and cultivated overnight. The next day, the cell culture medium was exchanged and cells were stimulated with the reagents of interest for 6 h, and the IL8 concentrations reached in the supernatants were determined using the OptEIA™ human IL8 Set (BD Biosciences) according to the supplier\'s protocols. After subtraction of the extinction of the medium control, IL8 concentrations were calculated based on IL8 standards included in the analysis.

RNase protection assay (RPA)
----------------------------

Cells were treated as indicated, washed, and stored at −80°C until total RNAs were prepared with the peqGOLD RNAPure reagent (PeqLab Biotechnologie GmbH) according to the manufacturer\'s instructions. Total RNAs were analyzed using customer Multi-Probe template sets (BD Biosciences) with respect to the expression of the indicated genes. Probe synthesis, hybridization, and RNase treatment were performed with RiboQuant In vitro transcription and RiboQuant Multi-Probe RNase Protection Assay Systems (BD Biosciences) according to the manufacturer\'s recommendations. After RNase treatment, the protected transcripts were resolved by electrophoresis on a denaturing polyacrylamide gel (5%) and analyzed using a PhosphorImager operated by the ImageQuant software (Molecular Dynamics).

DNA oligonucleotide microarray analysis
---------------------------------------

The customized DNA microarray used in this study contains three oligonucleotide probes per gene for 110 genes relevant for inflammation. The specificity of the probes has been validated as described in detail previously ([@bib16]). Fluorescent cRNA were prepared by reverse transcription of 3--5 μg of total RNA. Specifically, RNA was treated with DNase and double-stranded cDNAs followed by fluorophore-cRNAs that were synthesized using the cDNA synthesis system (Roche) and the MEGAscript T7 kit (Ambion) as directed by the manufacturers. 80 to 250 ng of double-stranded cDNA and 1.25 mM Cy3-UTP were used in each cRNA labeling reaction. Equal amounts (9 μg) of labeled cRNAs from each condition were hybridized individually to the DNA microarray in preprepared hybridization solution (MWG Biotech) at 42°C overnight and then washed sequentially in 2× SSC, 0.1% SDS, 1× SSC, and 0.5× SSC. Hybridized arrays were scanned at maximal resolution on a scanner (model 428; Affymetrix, Inc.). Fluorescence intensity values from TIFF images of Cy3 channels were integrated into one value per probe, normalized by the MAVI software (MWG Biotech), and further analyzed using Imagene 4.2 software (Biodiscovery). Genes whose expression changed by 1.5-fold on average and by at least 1.3-fold in each individual experiment were considered to be regulated by TNF or FasL, respectively. Genes whose expression ratio did not change were considered to be significantly expressed if the normalized signal intensity measured for this gene was two SDs higher than the average signal intensity obtained by comparing microarray results from five different cell lines.
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